Regencell Bioscience (RGC) has had the highest return since March 20, 2024 by a mid-cap US stock, returning 11,947.8%.
| ASSET | % RETURN |
|---|---|
Regencell Bioscience (RGC) | 11,947.75% |
Triumph (TGI) | 2,069.52% |
GeneDx (WGS) | 1,411.48% |
Quantum Computing (QUBT) | 1,209.4% |
CommScope (COMM) | 1,048.15% |
Anbio Biotechnology Class A Ordinary Shares (NNNN) | 867.87% |
Rigetti Computing (RGTI) | 830.17% |
Sezzle Inc Common Stock (SEZL) | 795.56% |
D-Wave Quantum (QBTS) | 673.18% |
Mesoblast (MESO) | 615.86% |
Ouster, Inc Common Stock (OUST) | 610.02% |
Verona Pharma PLC ADR (VRNA) | 588.04% |
Dave (DAVE) | 509.17% |
Nuscale Power (SMR) | 446.53% |
Terawulf (WULF) | 424.56% |
Hesai Group American Depositary Share, each ADS represents one Class B ordinary share (HSAI) | 396.89% |
Abivax SA American Depositary Shares (ABVX) | 383.13% |
Centrus Energy (LEU) | 361.52% |
Newegg Commerce (NEGG) | 359.18% |
Argan (AGX) | 356.64% |
Tutor Perini (TPC) | 336.87% |
IREN (IREN) | 328.98% |
SSR Mining (SSRM) | 319.5% |
VNET Group Inc DRC (VNET) | 308.95% |
American Superconductor (AMSC) | 301.67% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
